z-logo
open-access-imgOpen Access
Conversion of Enkephalin and Dermorphin into δ‐Selective Opioid Antagonists by Single‐Residue Substitution
Author(s) -
Tancredi Teodorico,
Salvadori Severo,
Amodeo Pietro,
Picone Delia,
Lazarus Lawrence H.,
Bryant Sharon D.,
Guerrini Remo,
Marzola Giuliano,
Temussi Piero A.
Publication year - 1994
Publication title -
european journal of biochemistry
Language(s) - English
Resource type - Journals
eISSN - 1432-1033
pISSN - 0014-2956
DOI - 10.1111/j.1432-1033.1994.tb20017.x
Subject(s) - dermorphin , naltrindole , chemistry , stereochemistry , opioid peptide , agonist , enkephalin , morpholine , peptide , moiety , opioid , opioid receptor , receptor , medicinal chemistry , biochemistry
The properties of di‐ and tri‐peptides containing 1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylic acid (Tic) in second position suggest that the message domain of opioid peptides can be composed of only two residues [Temussi, P. A., Salvadori, S., Amodeo, P., Guerrini, R., Tomatis, R., Lazarus, L. H., Picone, D. & Tancredi, T. (1994) Biochem. Biophys. Res. Commun. 198 , 933–9391. As a crucial test of the possibility that the Tyr‐Tic segment be a message domain in longer peptide sequences, we have inserted it in the sequences of two typical opioid peptides: [Leu]enkephalin, a non‐selective agonist, and dermorphin, a selective μ agonist. Here we report the synthesis and biological activity of [ l ‐Tic 2 ]enkephalin, [ l ‐Tic 2 ]dermorphin, [ l ‐Tic 2 ]dermorphin carboxylic acid and [ d ‐Tic 2 ]dermorphin: all [ l ‐Tic 2 ]peptides were converted from agonists to δ‐selective antagonists. The NMR conformational study in a dimethylsulfoxide/water cryoprotective mixture at low temperature shows diagnostic side‐chainside‐chain NOEs in the spectra of all [ l ‐Tic 2 ]peptides and hints that the 90° arrangement of the the two aromatic rings found in the cis‐Tyr‐ l ‐Tic moiety, typical of N ‐methyl naltrindole and other δ‐selective opiate antagonists, is responsible for the antagonist activity of all these peptides.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here